Alkermes
Company Snapshot
Founded: 1987
Entity Type: Public
Employees: 2,050
Region: U.S.
Revenue: $1,475.9 Millions
Revenue Year: 2025
Segment: Manufacturing and Royalty
Headquarter: Dublin, Ireland
Key Geographics: U.S., Ireland, Rest of the World
Corporate Address: Connaught House 1 Burlington Road Dublin 4, Ireland, D04 C5Y6 Tel. +353-1-772-8000 www.alkermes.com
Company Overview
Alkermes plc is a biopharmaceutical company that develops medicines for neurological disorders. Alkermes’s portfolio of proprietary medicines focuses on alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Its main products include Vivitrol, Lybalvi, and Aristada and Aristada Initio. Vivitrol is an opioid antagonist. Lybalvi (olanzapine and samidorphan) is used in adults to treat manic or mixed episodes that happen with bipolar 1 disorder. Aristada is used to treat schizophrenia in adults. Alkermes is headquartered in Ireland and has a corporate office and R&D center in Massachusetts, as well as a manufacturing facility in Ohio, U.S.
Financial Highlights (FY 2025)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Alkermes In News
Company's Business Segments
- Product Sales : The company various products such as VIVITROL, ARISTADA and ARISTADA INITIO and LYBALVI.
- Manufacturing and Royalty : In this segment company offers Long-acting INVEGA products, VUMERITY, RISPERDAL CONSTA and Others.
Applications/End User Industries
- Healthcare
- Biopharmaceutical
- Life Sciences
- Pharmaceuticals